Top

Published in:

01-07-2013 | Treatment of Autoimmunity

Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab

Authors: Francesco Caso, Luca Iaccarino, Silvano Bettio, Francesca Ometto, Luisa Costa, Leonardo Punzi, Andrea Doria

Published in: Immunologic Research | Issue 2-3/2013

Abstract

Pemphigus foliaceus (PF) and Behçet’s disease (BD) are immune-mediated conditions which are usually treated with corticosteroids, immunosuppressants, and, when refractory, with biologic agents. In both diseases, interleukin (IL)-6 serum levels are increased driving the immune-mediated inflammatory process. Tocilizumab is a humanized monoclonal antibody, targeting IL6-receptor, used in the treatment of rheumatoid arthritis. Besides the current indication, it has been recently administered to patients with refractory immune inflammatory diseases as an off-label treatment. Here, we report the case of a woman affected with PF and BD, who did not respond to corticosteroids, immunosuppressants, and biologic agents including adalimumab, anakinra, and infliximab. A complete, long-lasting, clinical, and serological remission was achieved only with tocilizumab. To the best of our knowledge, the association between PF and BD has never been reported. Moreover, only two cases of BD and no cases of PF treated with tocilizumab have been described to date. A literature review on the use of biologic agents on patients with PF and BD was also carried out.

Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet. 1999;354:667–72.PubMedCrossRef

Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev. 2010;10:84–9.PubMedCrossRef

Sticherling M, Erfurt-Berge C. Autoimmune blistering diseases of the skin. Autoimmun Rev. 2012;11:226–30.PubMedCrossRef

James KA, Culton DA, Diaz LA. Diagnosis and clinical features of pemphigus foliaceus. Dermatol Clin. 2011;29:405–12.PubMedCrossRef

Tampoia M, Giavarina D, Di Giorgio C, Bizzaro N, Diagnostic accuracy of enzyme-linked immunosorbent assays (ELISA) to detect anti-skin autoantibodies in autoimmune blistering skin diseases: a systematic review and meta-analysis. Autoimmun Rev. 2012. doi:10.1016/j.bbr.2011.03.031.

Zhu X, Zhang B. Paraneoplastic pemphigus. J Dermatol. 2007;34:503–11.PubMedCrossRef

Leshem YA, Katzenelson V, Yosipovitch G, David M, Mimouni D. Autoimmune diseases in patients with pemphigus and their first-degree relatives. Int J Dermatol. 2011;50:827–31.PubMedCrossRef

Sáez-de-Ocariz M, Granados J, Yamamoto-Furusho JK, López-Martínez A, Vega-Memije ME. Rheumatoid arthritis associated with pemphigus foliaceus in a patient not taking penicillamine. Skinmed. 2007;6:252–4.PubMedCrossRef

Malik M, Ahmed AR. Concurrence of systemic lupus erythematosus and pemphigus: coincidence or correlation? Dermatology. 2007;214:231–9.PubMedCrossRef

10.

Calebotta A, Cirocco A, Giansante E, Reyes O. Systemic lupus erythematosus and pemphigus vulgaris: association or coincidence. Lupus. 2004;13:951–3.PubMedCrossRef

11.

Hidalgo-Tenorio C, Sabio-Sánchez JM, Tercedor-Sánchez J, León-Ruíz L, Pérez-Alvarez F, Jiménez-Alonso J. Pemphigus vulgaris and systemic lupus erythematosus in a 46-year-old man. Lupus. 2001;10:824–6.PubMedCrossRef

12.

Narbutt J, Torzecka JD, Sysa-Jedrzejowska A, Pas HH. Pemphigus foliaceus in an 11-year-old boy with dermatomyositis: simple coincidence or familial immunological background? Br J Dermatol. 2003;148:838–9.PubMedCrossRef

13.

Black M, Marshman G. Dermatomyositis and pemphigus vulgaris: association or coincidence? Australas J Dermatol. 2011;52:e11–4.PubMedCrossRef

14.

Saadoun D, Wechsler B. Behcet’s disease. Orphanet J Rare Dis. 2012;7:20.PubMedCrossRef

15.

International Study Group for Behcet’s Disease. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335:1078–80.

16.

Pipitone N, Olivieri I, Salvarani C, Italian Society of Rheumatology. Recommendations of the Italian society of rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. Clin Exp Rheumatol. 2012;30:S139–61.PubMed

17.

Goebeler M, Herzog S, Bröcker EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol. 2003;149:899–901.PubMedCrossRef

18.

Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153:620–5.PubMedCrossRef

19.

Joly P, Mouquet H, Roujeau JC, D’Incan M, Gilbert D, Jacquot S, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(9):545–52.PubMedCrossRef

20.

Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol. 2007;143:1033–8.PubMedCrossRef

21.

Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology. 2007;214:310–8.PubMedCrossRef

22.

Fernando SL, O’Connor KS. Treatment of severe pemphigus foliaceus with rituximab. Med J Aust. 2008;189:289–90.PubMed

23.

Prodanovic EM, Korman NJ. A case of non-Hodgkin’s lymphoma-associated pemphigus foliaceus and use of rituximab for treatment. J Dermatolog Treat. 2008;19:1–3.PubMedCrossRef

24.

Serrão VV, Martins A, Páris FR, Lopes MP. Successful treatment of recalcitrant pemphigus foliaceus with rituximab. J Eur Acad Dermatol Venereol. 2008;22:768–70.PubMedCrossRef

25.

Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol. 2008;158:382–8.PubMedCrossRef

26.

Kim MR, Kim HC, Kim SC. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients. Dermatology. 2011;223:182–8.PubMedCrossRef

27.

Carvalho R, Maio P, Cunha D, Freitas I, Afonso A, Cardoso J. Rituximab in pemphigus foliaceous with autoantibodies against both Desmoglein 1 and Desmoglein 3. Eur J Dermatol. 2011;21:415–6.PubMed

28.

Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65:552–8.PubMedCrossRef

29.

Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011;165:646–51.PubMedCrossRef

30.

Kanwar AJ, Tsuruta D, Vinay K, Koga H, Ishii N, Dainichi T, Hashimoto T. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J Eur Acad Dermatol Venereol. 2013;27:e17–23.PubMedCrossRef

31.

Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166:405–12.PubMedCrossRef

32.

Kasperkiewicz M, Shimanovich I, Meier M, Schumacher N, Westermann L, Kramer J, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. 2012;166:154–60.PubMedCrossRef

33.

Reguiai Z, Tabary T, Maizières M, Bernard P. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J Am Acad Dermatol. 2012;76:623–9.CrossRef

34.

Matsukura S, Knowles SR, Walsh S, Shear NH. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients. Arch Dermatol. 2012;148:734–9.PubMedCrossRef

35.

Grekin SJ, Fox MC, Gudjonsson JE, Fullen DR. Psoriasiform pemphigus foliaceus: a report of two cases. J Cutan Pathol. 2012;39:549–53.PubMedCrossRef

36.

Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients adjuvant rituximab therapy of pemphigus. Arch Dermatol. 2012;18:1–6.

37.

Paradisi A, Cianchini G, Lupi F, Di Pietro C, Sampogna F, Didona B, et al. Quality of life in patients with pemphigus receiving adjuvant therapy. Clin Exp Dermatol. 2012;37:626–30.PubMedCrossRef

38.

Kasperkiewicz M, Eming R, Behzad M, Hunzelmann N, Meurer M, Schulze-Koops H, et al. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges. 2012;10:727–32.PubMed

39.

Gubinelli E, Bergamo F, Didona B, Annessi G, Atzori F, Raskovic D. Pemphigus foliaceus treated with etanercept. J Am Acad Dermatol. 2006;55:1107–8.PubMedCrossRef

40.

McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology. 1998;12:1763–9.PubMed

41.

Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis. 2010;69:i2–29.PubMedCrossRef

42.

van Vollenhoven RF. Rituximab—shadow, illusion or light? Autoimmun Rev. 2012;11:563–7.PubMedCrossRef

43.

Isenberg DA. Rituximab—it was the best of times, it was the worst of times. Autoimmun Rev. 2012;11:790–1.PubMedCrossRef

44.

Kasperkiewicz M, Schmidt E, Zillikens D. Current therapy of the pemphigus group. Clin Dermatol. 2012;30:84–94.PubMedCrossRef

45.

Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol. 2005;153:222–3.PubMedCrossRef

46.

Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol. 2005;153:448–9.PubMedCrossRef

47.

Vojáčková N, Fialová J, Vaňousová D, Hercogová J. Pemphigus vulgaris treated with adalimumab: case study. Dermatol Ther. 2012;25:95–7.PubMedCrossRef

48.

Shetty A, Marcum CB, Glass LF, Carter JD. Successful treatment of pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol. 2009;8:940–3.PubMed

49.

Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev. 2012;11:687–98.PubMedCrossRef

50.

Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41:61–70.PubMedCrossRef

51.

Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, et al. A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22:298–302.PubMedCrossRef

52.

Shapiro LS, Farrell J, Haghighi AB. Tocilizumab treatment for neuro-Behçet’s disease, the first report. Clin Neurol Neurosurg. 2012;114:297–8.PubMedCrossRef

53.

Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA. Resistant Behçet disease responsive to anakinra. Ann Intern Med. 2008;149:284–6.PubMedCrossRef

54.

Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol. 2010;29:209–10.PubMedCrossRef

55.

Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behçet’s disease with rituximab. Mod Rheumatol. 2008;18:306–8.PubMedCrossRef

56.

Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, et al. Rituximab in intractable ocular lesions of Behçet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13:246–52.PubMedCrossRef

57.

Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, et al., Overlap connective tissue disease syndromes. Autoimmun Rev. 2012. doi:10.1016/j.autrev.2012.06.004.

58.

Fonseca JE, Santos MJ, Canhão H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8:538–42.PubMedCrossRef

59.

Doria A, Zen M, Bettio S, Gatto M, Bassi N, Nalotto L, et al. Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev. 2012;12:22–30.PubMedCrossRef

60.

D’Auria L, Bonifati C, Mussi A, Agosto GD, Simone CD, Giacalone B. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw. 1997;8:383–7.PubMed

61.

López-Robles E, Avalos-Díaz E, Vega-Memije E, Hojyo-Tomoka T, Villalobos R, Fraire S, et al. TNFα and IL-6 are mediators in the blistering process of pemphigus. Inter J Dermatol. 2001;40:185–8.CrossRef

62.

Chriguer RS, Roselino AM, de Castro M. Glucocorticoid sensitivity and proinflammatory cytokines pattern in pemphigus. J Clin Immunol. 2012;32:786–93.PubMedCrossRef

63.

Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behcet’s disease. Autoimmun Rev. 2012;11:699–704.PubMedCrossRef

64.

Sun A, Wang YP, Chia JS, Liu BY, Chiang CP. Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-alpha level in patients with mucocutaneous type of Behcet’s disease. J Oral Pathol Med. 2009;38:401–5.PubMedCrossRef

65.

Akman-Demir G, Tüzün E, Içöz S, Yeşilot N, Yentür SP, Kürtüncü M, et al. Interleukin-6 in neuro-Behçet’s disease: association with disease subsets and long-term outcome. Cytokine. 2008;44:373–6.PubMedCrossRef

66.

Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity. 2012;45:7–35.PubMedCrossRef

67.

Direskeneli H. Autoimmunity vs autoinflammation in Behçet’s disease: do we oversimplify a complex disorder? Rheumatology (Oxford). 2006;45:1461–5.CrossRef

68.

Briani C, Doria A, Marcolongo R, Tognon S, Ruggero S, Toffanin E, et al. Increased titres of IgM anti-heparansulfate antibody in Behçet’s disease. Clin Exp Rheumatol. 2006;24:S104–7.PubMed

69.

Arakawa M, Dainichi T, Yasumoto S, Hashimoto T. Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus. J Dermatol Sci. 2009;53:228–31.PubMedCrossRef

70.

Hamzaoui K. Th17 cells in Behçet’s disease: a new immunoregulatory axis. Clin Exp Rheumatol. 2011;29:S71–6.PubMed

71.

Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40:1830–5.PubMedCrossRef

72.

Langier S, Sade K, Kivity S. Regulatory T cells: the suppressor arm of the immune system. Autoimmun Rev. 2010;10:112–5.PubMedCrossRef

73.

Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol. 2012;52:199–219.PubMedCrossRef

74.

Zen M, Gatto M, Domeneghetti M, Palma L, Borella E, Iaccarino L, Punzi L, Doria A. Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity—a comprehensive review. Clin Rev Allergy Immunol. 2013. doi:10.1007/s12016-013-8355-1.

Title: Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab
Authors: Francesco Caso
Luca Iaccarino
Silvano Bettio
Francesca Ometto
Luisa Costa
Leonardo Punzi
Andrea Doria
Publication date: 01-07-2013
Publisher: Springer-Verlag
Published in: Immunologic Research / Issue 2-3/2013
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-013-8411-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2-3/2013

Julius M. Cruse: His rendezvous with immunology

Rationale for treating primary Sjögren’s syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab)

A subset of anti-rotavirus antibodies directed against the viral protein VP7 predicts the onset of celiac disease and induces typical features of the disease in the intestinal epithelial cell line T84

Silicone implant incompatibility syndrome (SIIS): A frequent cause of ASIA (Shoenfeld’s syndrome)

Unraveling the soul of autoimmune diseases: pathogenesis, diagnosis and treatment adding dowels to the puzzle

Genetics and autoantibodies